The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jessica Macomber Fye - JP Morgan Chase & Co, Research Division - Analyst
: Just a few -- first, just following upon Chris' question, sorry, if I missed this. What was the prior deadline for starting the pivotal studies?
And what's the new deadline under the Bristol collaboration?
Then to confirm the melanoma update that you mentioned at ASCO, did you say that will not have data in the abstract? And just to
confirm, did you also say that there has been further deepening of responses since the SITC update? And then lastly, on the sarcoma
IST data at ASCO, should we expect data from sarcoma patients in that abstract?
Question: Jessica Macomber Fye - JP Morgan Chase & Co, Research Division - Analyst
: And will patient data be in the abstract for melanoma?
Question: Jessica Macomber Fye - JP Morgan Chase & Co, Research Division - Analyst
: Got it. Can I just ask 1 more for Howard, in the beginning when you were talking about 181, and I think you mentioned a potential
adcom, did you say it could be in the August timeframe, i.e., very close to the PDUFA date?
Question: George Farmer - BMO Capital Markets Equity Research - Analyst
: I want to dig into a bit more on the melanoma data that we'll be seeing at ASCO. Did you say that you have not hit your median PFS
as of 12 months or as of today?
Question: George Farmer - BMO Capital Markets Equity Research - Analyst
: Okay. Great. And can you comment as to how many patients are remaining on treatment as of today?
Question: George Farmer - BMO Capital Markets Equity Research - Analyst
: Okay. And also getting back to previous question about 181, it does seem a little tight to have the panel so close to the PDUFA? I
mean is it possible that the PDUFA could be extended, again?
Question: Arlinda Anna Lee - Canaccord Genuity Limited, Research Division - Analyst
: I guess I was pretty intrigued about conversion of PD-L1 patients at an earlier conference this year. And I was wondering if we might
see a broader additional information to that effect at -- on any of your data sets in the presentations that you've highlighted that
are coming out later this year.
Secondly, I'd be curious about the triple-negative breast cancer dataset, and when -- what the scope of that dataset might look like?
| 
